Robin Kate Kelley

机构：University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of San Francisco · ORCID：0000-0002-1984-2430

发表论文 516 篇 · 总被引 74470 次 · h-index 93

代表论文

• Cholangiocarcinoma 2026: status quo, unmet needs and priorities (2025 · Nature Reviews Gastroenterology & Hepatology · 被引 53)
• Hallmarks of liver cancer: Therapeutic implications (2026 · Cell · 被引 9)
• Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis (2025 · Liver Cancer · 被引 3)
• A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma (2026 · Journal of Hepatology · 被引 2)
• Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses (2026 · Hepatology · 被引 1)
• Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma. (2026 · Journal of Clinical Oncology · 被引 1)